| BACKGROUND
This poor uptake has been attributed by physicians in part to paucity of randomised controlled trial (RCT) data, the lack of a standard treatment protocol, and uncertainty about long-term safety of FMT. 3 Clostridium difficile infection occurs mainly in the elderly and those with significant chronic illnesses. 1 The long-term cure rate from standard first line antibiotics (metronidazole or vancomycin) is low with CDI re-occurring after apparent resolution in about 35% of patients. 4 Recurrent CDI is defined as complete recovery without symptoms followed by at least one further episode of diarrhoea confirmed to be secondary to CDI. Recurrent attacks of CDI expose patients to risk of complications such as toxic dilatation of the colon and septicaemia, which are associated with high mortality. Commonly, tapering doses of vancomycin are used for recurrent and refractory CDI although the effectiveness of this therapy is uncertain with sustained cure rates reportedly ranging widely between 49%
and 100%. 5 While fidoxamicin has been shown to be more effective than vancomycin in the resolution of CDI as a first-line agent, this agent has not been tested in recurrent CDI. 6, 7 Faecal microbiota transplantation for the treatment of CDI was attempted first in the modern era by Eiseman et al. 8 in a small number of patients. Over the past decade or so, FMT has been studied by several centres worldwide for management of recurrent and refractory CDI. However, uncontrolled studies make up the bulk of the supporting evidence. Previous systematic reviews and meta-analyses either have methodological limitations as they have a restrictive selection criteria, do not have a comprehensive search strategy or do not consider the effect of different modalities of preparation or delivery of FMT.
Moreover, they do not include the most recent evidence, which to date includes more than five RCTs. [9] [10] [11] [12] In this systematic review and meta-analysis, we therefore aim to address these issues to bring the evidence on FMT in recurrent and refractory CDI up to date. 13, 14 2 | ME TH ODS
| Objectives
To systematically evaluate the effectiveness of FMT as treatment for recurrent and refractory CDI.
The review and meta-analysis were undertaken in line with guidance from the Cochrane Handbook of Systematic Reviews of Interventions, and reported in line with preferred reporting items for systematic reviews and meta-analysis. Search results were entered into a bibliography manager and duplicate entries removed.
| Study selection
Titles and abstracts of each article were screened for relevance.
Copies of relevant articles were obtained and assessed for inclusion in the review using the criteria below. Screening and selection were undertaken independently by two reviewers and any disagreements resolved through discussion. The reason for not-selecting studies for review was recorded.
| Type of studies
Randomised controlled trials, non-randomised trials and case series with 10 or greater participants were included. Studies published in abstract only format (for example, from conference supplements)
were only included if they were RCTs.
| Type of participants
Studies recruiting patients of all ages with refractory or recurrent CDI were included. Patients include those with ongoing diarrhoea without resolution of symptoms despite standard antimicrobial therapy. Recurrent and refractory CDI was taken as defined by the authors.
| Comparator
For comparative study designs, there was no restriction on the type of comparator.
Primary outcome
Studies reporting clinical resolution of CDI based on improvement of symptoms or negative C. difficile stool culture or toxin were included.
| Data extraction
Data were extracted using a predesigned collection form on characteristics of study design, participants, type of CDI (recurrent and/or refractory) and outcomes. In addition, data were extracted on donor screening, procedural aspects (FMT preparation, pre-medications and number of infusions) to establish variation in practice. Data on adverse events were also collected.
There was no missing data or unclear information that necessitated contacting study authors for clarification. For papers not published in English, partial translations were undertaken (in one case).
Data extraction and risk of bias assessment were undertaken by two reviewers independently. If there were any discrepancies, a third reviewer was consulted (in one case).
| Risk of bias
Randomised controlled trials were assessed with the Cochrane Collaboration's risk of bias tool. 13 For non-randomised trials, the same tool was to be used without application of criteria related to randomisation. Case series were assessed using the Centre for Reviews and Dissemination guidance. 
| Data assessment and analysis
The effect of FMT on clinical resolution of recurrent and refractory CDI was evaluated by analysing studies with direct comparison against a non-FMT arm. The overall effect of FMT was analysed using data from all studies (including the FMT arm data from RCTs).
The author's definition of outcome of CDI resolution was used at the time point specified by the author following the delivery of FMT. To study the effect of multiple infusions, the data were analysed to compare rate of clinical resolution if only a single infusion was administered and if more than one infusion was delivered. 
| Statistical analysis
For the primary outcome, pooled estimates of relative risk from the RCTs, and response rates from case series, were estimated with a random effects model using the method of DerSimonian and Laird. 16, 17 For the latter, the pooled estimate was calculated after the FreemanTukey Double Arcsine Transformation was applied to stabilise the variances facilitating synthesis of studies with 100% response rate. 18 Exact confidence intervals were calculated for the individual studies.
Heterogeneity was assessed using the I 2 statistic and calculation of 95% prediction intervals for the response proportion in a new study. 19, 20 The latter were calculated using a logistic regression model with a random intercept. 3 | RESULTS
| Study characteristics
The initial search identified 2097 publications. Of these, 1179 duplicates were excluded and an additional 615 were removed after screening titles and abstracts. Consequently, 303 papers were retrieved in full text. Of these 19 were systematic reviews from which no additional papers were identified. From the remaining 284 papers, 102 were overviews, summaries, opinion pieces and narrative reviews, 83 were case reports or case series with a sample size of less than 10 patients and 62 were case series published in abstract form. Therefore, 37 papers reporting studies met the selection criteria ( Figure 1 ).
The 37 included studies are summarised in Table S1 . Table S1 elaborates on the primary response rate data and assessment of study quality. Seven studies were RCTs (of which two were only published in abstract form) and 30 were case series. The different arms of the RCT data are summarised in | 481 studies had similar cohorts with regard to age and gender and similar response rates were observed in older and younger groups and those with male or female predominance as shown in Table S1 .
There was a female preponderance in the studies with a male:female distribution of 2:3. No studies solely used toxin negativity to define clinical resolution. Prior endoscopic evaluation was undertaken in six studies. 
| Procedural aspects

FMT preparation
In eight studies, the solvent was water, saline in 20 and glycerol was used as a cytoprotectant in the three studies using frozen stool preparations. The remaining studies did not describe the diluent used to make up the transplant material. Where stated, time from collection to administration varied from 1 hour to 8 weeks (frozen stool) whilst the median time was 6 hours for studies using fresh stool samples. Quantity and volume of FMT material was very variable. In the studies using the upper route of delivery, the volume of material varied from 25 to 500 mL and the mass of faecal material also varied widely from 6 g up to about 140 g (median 40 g). In the studies reporting on the lower GI route of delivery, the volume of FMT was reported in 19 and this ranged from 100 to 1000 mL with a mean • Systematic reviews -19
• Other reviews -102
• Case reports or case series with a sample size < 10 -83
• Case series only in an abstract format -62) Studies included in qualitative synthesis (n=37) F I G U R E 1 Flow chart of search volume of about 450 mL. The fresh mass of faecal matter used was variably reported from 30 to 152 g (median of 86 g). Two RCTs used capsulated forms of stool, however, further details on the preparation of these capsules was not available as the data were only published in an abstract form. 26, 32 Pre-medication Standard colonoscopy bowel preparation was used in all studies undertaking FMT via the lower GI route. Proton pump inhibitors were given in most studies using the upper route with the exception of the Van Nood RCT. 22 The use of anti-diarrhoeals to prolong retention of the faecal suspension in the colon was also reported in two studies. Antibiotics were generally stopped 1-2 days before FMT with the exception of the van Nood RCT, where antibiotics were continued until the day of the treatment. 22 
Number of infusions
Twenty-four studies allowed more than one infusion/treatment of FMT in the event of failure of response. Of the 13 studies that only performed a single infusion of FMT nine were done using the lower GI route, three used only the upper GI route and one used either route. 26, 27, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] In the remaining studies, FMT was administered up to four times for recurrent or unresolved symptoms.
| Assessment of study quality
The seven RCTs were assessed to have a low risk of bias and demonstrated adequate randomisation with concealed automated allocation and performed an intention-to-treat analysis. For case series, although selection criteria were defined in most of these studies, all mentioned or implied consecutive recruitment of patients.
Patients were followed up until achievement or failure of the primary outcome. Consequently, few studies reported long term outcomes and adverse events. Follow-up ranged from 10 weeks to 8 years.
| Efficacy of FMT
Most studies differed in their definition/criteria for resolution of CDI. Hence, the author's definition of outcome of CDI resolution at their specified time point following the delivery of FMT was used.
Based on the variability in definitions used in the literature, it was not possible to clearly separate data on "recurrent" vs "refractory"
CDI. There were no true placebo controlled trials investigating the efficacy of FMT.
| Response to FMT-RCTs
There were three RCTs that compared FMT to a non-FMT intervention. In the two RCTs comparing FMT to vancomycin, the pooled rel- either a low or high dose of capsules. 32 The abstract reports that the five non-responders at 8 weeks were all given a high dose of capsules with cure in 4.
| Response to FMT-all studies
The mean pooled overall response for FMT in recurrent and refractory CDI based on all the included 37 studies regardless of the number of infusions was 92% (95% CI 89%-94%) with likely moderate heterogeneity (I 2 =59%) (Figure 2) . From the 34 studies that presented efficacy data for a single FMT infusion, the mean pooled response rate was 84% (95% CI 79%-89%) with a likely high degree of heterogeneity (I 2 =84%). For a single infusion a 95% prediction interval for the response proportion in a new study is 49%-96%. On analysis by funnel plot, studies were not symmetrically distributed about the pooled estimate possibly indicating an absence of some smaller and medium sized studies with findings that, although favourable, are not as favourable as other small studies. There are many possible reasons for this including chance, small study effects and publication bias. When this funnel plot asymmetry was adjusted for, the efficacy of one or more FMT infusions was only reduced by a small amount to 79% (95% CI 73%-84%) ( Figure S1 ).
The case series had cure rates ranging from 68% to 100% with only one study having an overall response rate of under 75% and eight case series demonstrating a response rate of 100% (although there was incomplete follow-up in some of these studies).
Only one study addressed the efficacy of FMT for treatment of CDI in immunocompromised patients. 30 This study included a series of patients with IBD, solid organ transplants on immunosuppression, HIV and cancers. The CDI cure rate observed after a single FMT was 78%, with an overall cure rate of 89% following a second transplant.
| Comparison between upper GI and lower GI routes of delivery
The RCT that compared nasogastric (upper GI) vs colonic delivery of FMT reported a cure rate of 60% at 8 weeks with a single infusion and an overall cure rate 80% after second infusion when delivered via NG. 28 The cure rate with colonic delivery was 80% with a single infusion at 8 weeks and an overall cure rate of 100% after a second infusion.
Of the remaining studies, 25 case series and seven RCTs had separate outcome data for modes of FMT delivery. Twenty-two delivered FMT by the lower GI route (colonoscopy or retention enema) and 11 delivered FMT by the upper gastrointestinal route (upper GI endoscopy, nasogastric tube or naso-jejunal tube).
Results are displayed in Figure 3 . The pooled response of CDI to 
| Comparison of freshly prepared vs frozen FMT
In the RCT by Lee, patients received either FMT prepared no more than 5 hours earlier (n=111) or FMT frozen for up to 30 days (n=108). 24 The clinical resolution of diarrhoea using intention-to-treat analysis showed no evidence of a difference in outcome between preparations, with a relative risk of failure 
Of the other studies, 30 case studies used fresh stool and four studies (two case series, two RCTs) used frozen stool to prepare FMT and a response rate was calculable for each group. For the fresh FMT studies, the overall response rate was 92% (95% CI 89%-95%) with moderate heterogeneity between the studies (I 2 =54%).
When adjusted for funnel plot asymmetry, the overall response rate was 87%. The overall response in frozen FMT studies was 93%
(95% CI 87%-97%) with minimal observed heterogeneity between the studies (I 2 =19%). There were insufficient studies to assess funnel plot asymmetry. There was no evidence of a difference in response between the two groups (P=.84) (Figure 4 ). Analysis of a single infusion revealed a response rate of 85% (95% CI 79%-90%) for fresh FMT and a lower response rate of 68% (95% CI 47%-86%) for frozen FMT, but there was only very weak statistical evidence of a difference (P=.10).
| Adverse events
The RCT by Van Nood et al. reported no significant adverse events (SAEs) in 16 patients treated with FMT, however, there were two urinary tract infections and one patient suffered from choledocholithiasis. 22 No SAEs related to FMT were reported in other RCTs.
Transient mild diarrhoea and cramping was very common in the administered by colonoscopy, chills were observed more frequently in autologous group. 27 Rates of other minor AEs did not differ significantly between groups.
In the case series, most side effects were minor and often transient:
bloating, belching, abdominal cramps, pain or discomfort, nausea, vomiting, excess flatulence, constipation, transient fever, urinary tract infections, self-limiting diarrhoea, and irregular bowel movement being seen.
However, recurrent and refractory CDI negative diarrhoea or worsening diarrhoea following FMT was also reported although the duration of this adverse event was not reported. 37, 44 The data from these case series did not allow an assessment of any differences in adverse events by route of treatment or use of fresh or frozen transplant.
There were no reported cases of aspiration following FMT delivery via the upper GI route. In one case, the patient vomited immediately after FMT application via nasogastric tube. 45 There was only one reported case of mucosal tear and micro perforation following colonoscopic delivery of FMT. 30, 46 Hospitalisation with self-limited FMT related abdominal pain, was reported in one patient. 30 There were 50 deaths reported in the studies reviewed, however, these were almost all due to critical illness of elderly patients with multiple comorbidities or unrelated illness and were not directly attributed to the FMT. However, there was a death as a result of aspiration at the time of sedation for the colonoscopy to administer the FMT. 30 Two patients with recurrent diarrhoea and initial response to the FMT died subsequently from complications of ileus and colonic perforation. Four deaths in patients infected with the ribotype 027 strain who did not respond to FMT and died within 3 months were also reported. 
Of note, a case series of FMT in 80 immunocompromised patients with 3 month follow-up did not report any serious adverse events. 30 However, four patients with inflammatory bowel disease in this cohort experienced a flare up of their condition after FMT. Similarly a case series of 146 elderly patients that were followed up for 1 year did not report any serious adverse events. 48 
| DISCUSSION
This systematic review and meta-analysis has demonstrated that FMT is a highly effective treatment for resolution of recurrent and refractory CDI. Even the most conservative analysis gives an estimate of 49% response rate for FMT in this setting based on the lower prediction interval for a single infusion. Previous systematic reviews and meta-analyses have reported the marked efficacy of FMT for treatment of CDI in the range of 88%-92%, similar to our findings. 9, 10 These, however, pre-dated or failed to include the five recent RCTs and included far fewer case series. 23, 24 There is good agreement between the efficacy demonstrated in observed response rates in the seven RCTs (only three of which have a non-FMT comparator arm)
performed to date and the reports from case series. The limited data on mortality and SAEs suggests that FMT is safe and generally well tolerated, even in sick immunocompromised elderly patients. No previous meta-analysis has compared fresh and frozen FMT in treatment of recurrent CDI, and the present study shows no difference in efficacy between these modes of stool preparation. The review also demonstrates that repeated infusions of FMT in nonresponders resulted in a higher cure rate albeit with some limited data for this analysis. Previous reviews have suggested that the efficacy for lower GI route is greater than upper GI route (Kassam et al.; 91% vs 80% respectively [P=.046]). 10 We have however shown that this difference was no longer significant when efficacy with only a single infusion was analysed.
With regard to attempting to differentiate between the efficacy of FMT for recurrent or refractory CDI, we found that the distinction between recurrent and refractory disease in the case series is often vaguely reported and not robust enough to allow for meaningful sub-group analysis. Similarly, previous reviewers have reported that no studies have compared refractory CDI to standard therapy and from the small numbers of patients being treated for solely refractory CDI meaningful analysis is difficult. 11, 12 This systematic review and meta-analysis is a comprehensive ascertainment of the available evidence through a detailed search strategy, and includes the seven RCTs to date. Structured analyses were performed to address key issues with regard to storage and administration of FMT that may improve wider uptake of this treatment strategy. There are, however, limitations to our analysis. This review is focussed on FMT and, as such, we have not included emerging data from investigations using faecal bacteriotherapy in which the microbiota is altered or in which specific bacteria are infused. 25, 49, 50 Short-term adverse events were reported in almost all the studies, however, there was lack of consistency in long-term follow-up for adverse events in uncontrolled studies and this was often reported on an ad-hoc basis. Follow-up was also limited to 10-13 weeks in RCTs. Most adverse events were self-limiting gastrointestinal symptoms including abdominal cramps, constipation, diarrhoea and usually occurred within 24 hours of the procedure and resolved within a week of the FMT. Deaths reported following FMT were almost always due to inter-current illness unrelated to CDI, FMT and overt failure to respond to FMT. On the whole, the current evidence suggests a good short-term safety of FMT, however, data are limited and uncertainty remains concerning unrecognised longterm consequences. It should also be noted that in this review studies were selected based on whether they reported an outcome related to resolution of CDI and that case series with less than ten patients were not analysed. Thus, it could be argued that this review is not comprehensive of all studies that might report adverse events.
Despite uncertainty FMT for the treatment of CDI associated colitis has been adopted as the biological rationale for its use is compelling and the treatment is cheap. The second line antibiotic treatment for CDI associated colitis after standard antibiotics (metronidazole and vancomycin) is fidaxomicin and this is vastly more expensive than FMT. 1 Moreover, there is no current evidence for fidaxomicin in the treatment of recurrent CDI and as yet no direct comparison of the effectiveness of this antibiotic against FMT.
In the UK, NICE has approved FMT "for patients for with recurrent CDI that have failed to respond to antibiotics and other treatments". 2 However, despite this official stamp of approval, standards of governance with respect to the procedure itself remain undefined. This is perhaps particularly pertinent now that manipulation of the microbiome is being considered in younger cohorts of patients for indications other than CDI associated colitis. 51, 52 Most studies appear to comply with the donor screening criteria outlined by the American Gastroenterology Association. International Consensus has highlighted current uncertainties concerning route of delivery, donor selection (household members/ healthy volunteers), the place of routine pre-treatment with antibiotics and bowel preparation and, in the light of long term safety concerns, the desirability of establishing a patient registry. 55 The utility of frozen FMT has gained significant interest as it allows the ability to deliver treatment on demand and to a wider population. As a result, recent regulatory discussions concerning FMT provision in the European Union have led to the situation that FMT use in the context of clinical trials is to be controlled by regulatory authorities. 56 Data are beginning to emerge regarding the association of microbiome alteration with response to FMT. In a recent study from the USA, the authors reported specific gut microbiota signatures associated with response to or recurrence after FMT. 57 This raises the possibility of predicting which patients may not respond to primary treatment with antibiotics and those then likely to need FMT. In another intriguing study from this group, it was reported that microbiota changes associated with bile salt metabolism following FMT may also indicate patients likely to progress to recurrent CDI and the need for FMT. 58 In the future, it is likely that we will see further data emerging from investigators who prepare "designer" FMT or by culturing specific organisms in vitro particularly as we better understand microbiota profiles which differentiate health from disease and the profile which is associated with successful FMT. 49, 50 In conclusion, FMT appears to be an effective and apparently safe treatment strategy for recurrent and refractory CDI. The efficacy is similar in both controlled and uncontrolled studies. The current data are relatively heterogeneous with regard to the methodology for transplantation and the outcome measure for resolution of CDI. While this could be explored with the current evidence base to refine estimates and potentially suggest effect modifiers, the effect of FMT on resolution of recurrent/refractory CDI is markedly evident and appears to be quantitatively in excess of that seen with other anti-microbial therapies such as vancomycin. Further studies should be of robust design and focus on determining the optimal procedures and longterm outcomes and side effects of FMT in order that FMT is available to help alleviate the burden of this significant iatrogenic hazard.
